Introduction NiKang Therapeutics is a biotech company in the early stages of development, specializing in creating small molecule oncology drugs to address the medical needs of patients who currently have limited treatment options. The company utilizes a target structure biology-informed approach, combined with structure-based drug design, to streamline the discovery and development process of their proprietary drug candidates. This methodology allows for the rapid identification and advancement of drug candidates with optimal pharmacological properties into clinical trials. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Proteolysis-targeting chimeras (PROTAC) | 1 |
Target |
Mechanism CDK4 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date03 Feb 2015 |
Target |
Mechanism HIF-2α inhibitors |
Active Org. NiKang Therapeutics, Inc.Startup |
Originator Org. NiKang Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK2 modulators |
Active Org. NiKang Therapeutics, Inc.Startup |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date19 Sep 2024 |
Sponsor / Collaborator NiKang Therapeutics, Inc.Startup |
Start Date23 Feb 2024 |
Sponsor / Collaborator NiKang Therapeutics, Inc.Startup |
Start Date28 Jul 2023 |
Sponsor / Collaborator NiKang Therapeutics, Inc.Startup [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Imdatifan ( HIF-2α ) | Metastatic Renal Cell Carcinoma More | Phase 2 |
Palbociclib ( CDK4 x CDK6 ) | Metastatic Clear Cell Renal Cell Carcinoma More | Phase 2 |
NKT-3964 ( CDK2 ) | Metastatic endometrial cancer More | Phase 1 |
NKT-3447 ( CDK2 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
KRAS G12D Inhibitor (NiKang Therapeutics) ( KRAS G12D ) | Neoplasms More | Preclinical |